Distinguished in Necrotizing Vasculitis

Oleg B. Iaremenko

T. Shevchenko Boulevard, 13, 
Kyiv, UA 
Distinguished in Necrotizing Vasculitis
T. Shevchenko Boulevard, 13, 
Kyiv, UA 
OverviewLocationsClinical Research

Overview

Oleg Iaremenko practices in Kyiv, Ukraine. Mr. Iaremenko is rated as a Distinguished expert by MediFind in the treatment of Necrotizing Vasculitis. His top areas of expertise are Necrotizing Vasculitis, Necrosis, Vasculitis, and Systemic Lupus Erythematosus (SLE).

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

T. Shevchenko Boulevard, 13, Kyiv, 01601, Ukraine

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: LY3361237
Study Phase: Phase 2
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
View 1 Less Clinical Trial

10 Total Publications

Clinical and laboratory pattern of patients with systemic lupus erythematosus seropositive for rheumatoid factor.
Clinical and laboratory pattern of patients with systemic lupus erythematosus seropositive for rheumatoid factor.
Journal: Reumatologia
Published: June 08, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Iaremenko's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile